Silverback falls on hard times, axing lead I/O candidates and laying off more than a fourth of staff
April 7, 2022
Silverback Therapeutics became the latest biotech to undertake a “strategic realignment” Thursday, revealing it would drop its two lead cancer programs — sending it back to the preclinical drawing board — and lay off more than a quarter of its staff.
Read the source article at endpts.com
2022-04-01 11:51:25
